EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSPNYG00000007824
Gene Symbol: GABRG3
4 Cross references
214 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSPNYG00000018192
Gene Symbol: GABRG3
4 Cross references
215 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSPNYG00000011129
Gene Symbol: GABBR1
1 Cross references
186 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSPNYG00000018663
Gene Symbol: GABBR1
3 Cross references
197 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSPNYG00000008120
Gene Symbol: GLP2R
3 Cross references
204 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSPNYG00000022497
Gene Symbol: GCGR
1 Cross references
164 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSPNYG00000000134
Gene Symbol: LOC102212086
2 Cross references
206 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSPNYG00000000265
Gene Symbol: LOC102193400
3 Cross references
205 Possible Orthologues:

Glucokinase

Ensembl ID : ENSPNYG00000007097
Gene Symbol: GCK
3 Cross references
211 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSPNYG00000004543
Gene Symbol: GBA1
3 Cross references
251 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSPNYG00000000152
Gene Symbol: GRIA1
3 Cross references
251 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSPNYG00000021331
Gene Symbol: GRIA2
4 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).